You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

357 Results
Guidelines and Advice
Updated
Aug 2025
Drug
Other Name(s): Vitrakvi®
Dec 2025
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    letrozole
Dec 2025
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI), 
Lung, 
Neuroendocrine (Lung)
Intent: Palliative
Funding:
ODB - General Benefit
    lanreotide
Updated
Jan 2026
Guidelines and Advice
Status: In-Review
ID: 4-3
Version: 4
Jul 2017
Symptom Management

Pages